Baseline characteristics, management, and predictors of early mortality in cardiogenic shock: insights from the FRENSHOCK registry.
Cardiogenic shock
Epidemiology
Mortality
Organ support
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
15
10
2021
received:
11
04
2021
accepted:
11
11
2021
pubmed:
2
1
2022
medline:
26
3
2022
entrez:
1
1
2022
Statut:
ppublish
Résumé
Published data on cardiogenic shock (CS) are scarce and are mostly focused on small registries of selected populations. The aim of this study was to examine the current CS picture and define the independent correlates of 30 day mortality in a large non-selected cohort. FRENSHOCK is a prospective multicentre observational survey conducted in metropolitan French intensive care units and intensive cardiac care units between April and October 2016. There were 772 patients enrolled (mean age 65.7 ± 14.9 years; 71.5% male). Of these patients, 280 (36.3%) had ischaemic CS. Organ replacement therapies (respiratory support, circulatory support or renal replacement therapy) were used in 58.3% of patients. Mortality at 30 days was 26.0% in the overall population (16.7% to 48.0% depending on the main cause and first place of admission). Multivariate analysis showed that six independent factors were associated with a higher 30 day mortality: age [per year, odds ratio (OR) 1.06, 95% confidence interval (CI): 1.04-1.08], diuretics (OR 1.74, 95% CI: 1.05-2.88), circulatory support (OR 1.92, 95% CI: 1.12-3.29), left ventricular ejection fraction <30% (OR 2.15, 95% CI: 1.40-3.29), norepinephrine (OR 2.55, 95% CI: 1.69-3.84), and renal replacement therapy (OR 2.72, 95% CI: 1.65-4-49). Non-ischaemic CS accounted for more than 60% of all cases of CS. CS is still associated with significant but variable short-term mortality according to the cause and first place of admission, despite frequent use of haemodynamic support, and organ replacement therapies.
Identifiants
pubmed: 34973047
doi: 10.1002/ehf2.13734
pmc: PMC8788015
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
408-419Informations de copyright
© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
ESC Heart Fail. 2022 Feb;9(1):408-419
pubmed: 34973047
Eur J Heart Fail. 2015 May;17(5):501-9
pubmed: 25820680
Ann Intern Med. 2008 Nov 4;149(9):618-26
pubmed: 18981487
Catheter Cardiovasc Interv. 2019 Jul 1;94(1):29-37
pubmed: 31104355
JAMA. 2005 Jul 27;294(4):448-54
pubmed: 16046651
Circ Cardiovasc Qual Outcomes. 2019 Mar;12(3):e005618
pubmed: 30879324
J Am Coll Cardiol. 2017 Apr 18;69(15):1913-1920
pubmed: 28408020
Circulation. 2009 Mar 10;119(9):1211-9
pubmed: 19237658
Int J Cardiol. 2017 Oct 1;244:213-219
pubmed: 28676243
Eur J Heart Fail. 2020 Aug;22(8):1315-1341
pubmed: 32469155
J Am Coll Cardiol. 2019 Oct 29;74(17):2117-2128
pubmed: 31548097
Circ Cardiovasc Qual Outcomes. 2016 Mar;9(2):117-25
pubmed: 26884615
Am J Cardiol. 2018 Sep 15;122(6):1104-1110
pubmed: 30072134
J Clin Med. 2020 Mar 28;9(4):
pubmed: 32231121
N Engl J Med. 2012 Oct 4;367(14):1287-96
pubmed: 22920912
Arch Cardiovasc Dis. 2019 May;112(5):343-353
pubmed: 30982720
Am Heart J. 2019 Jul;213:18-29
pubmed: 31078113
Eur J Heart Fail. 2017 Oct;19(10):1242-1254
pubmed: 28463462
Circulation. 2016 Oct 25;134(17):1224-1237
pubmed: 27777292
JACC Heart Fail. 2020 Nov;8(11):903-913
pubmed: 33121702
Eur Heart J. 2012 Oct;33(20):2535-43
pubmed: 22927559
Circulation. 2017 Oct 17;136(16):e232-e268
pubmed: 28923988
Circ Heart Fail. 2020 Sep;13(9):e007099
pubmed: 32900234
Am Heart J. 1999 Feb;137(2):313-21
pubmed: 9924166
Catheter Cardiovasc Interv. 2020 Sep 1;96(3):E213-E219
pubmed: 31925996